Cyteir Therapeutics, Inc.
CYT · NASDAQ
9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Market Cap | $102 | $93 | $65 | $58 |
| - Cash | $129 | $134 | $137 | $147 |
| + Debt | $0 | $0 | $0 | $1 |
| Enterprise Value | -$27 | -$41 | -$72 | -$88 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | – |
| EBITDA | -$5 | -$9 | -$13 | -$9 |
| % Margin | – | – | – | – |
| Net Income | -$4 | -$8 | -$12 | -$7 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.098 | -0.24 | -0.32 | -0.21 |
| % Growth | 59.2% | 25% | -52.4% | – |
| Operating Cash Flow | -$5 | -$4 | -$10 | -$7 |
| Capital Expenditures | $0 | $0 | $0 | -$0 |
| Free Cash Flow | -$5 | -$4 | -$10 | -$7 |